Literature DB >> 25992271

Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series).

Maria A Cavasin1, Kurt R Stenmark2, Timothy A McKinsey1.   

Abstract

Reversible lysine acetylation has emerged as a critical mechanism for controlling the function of nucleosomal histones as well as diverse nonhistone proteins. Acetyl groups are conjugated to lysine residues in proteins by histone acetyltransferases and removed by histone deacetylases (HDACs), which are also commonly referred to as lysine deacetylases. Over the past decade, many studies have shown that HDACs play crucial roles in the control of left ventricular (LV) cardiac remodeling in response to stress. Small molecule HDAC inhibitors block pathological hypertrophy and fibrosis and improve cardiac function in various preclinical models of LV failure. Only recently have HDACs been studied in the context of right ventricular (RV) failure, which commonly occurs in patients who experience pulmonary hypertension (PH). Here, we review recent findings with HDAC inhibitors in models of PH and RV remodeling, propose next steps for this newly uncovered area of research, and highlight potential for isoform-selective HDAC inhibitors for the treatment of PH and RV failure.

Entities:  

Keywords:  epigenetics; histone deacetylases; pulmonary hypertension; right ventricle

Year:  2015        PMID: 25992271      PMCID: PMC4405717          DOI: 10.1086/679700

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  89 in total

1.  Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”.

Authors:  Lan Zhao; Chien-Nien Chen; Nabil Hajji; Eduardo Oliver; Emanuele Cotroneo; John Wharton; Martin R Wilkins; Daren Wang; Min Li; Kurt R Stenmark; Timothy A McKinsey; Peter Buttrick
Journal:  Circulation       Date:  2013-04-09       Impact factor: 29.690

Review 2.  An update on medical therapy for pulmonary arterial hypertension.

Authors:  Yan Wu; Dermot S O'Callaghan; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

3.  HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.

Authors:  Jeffrey P Cardinale; Srinivas Sriramula; Romain Pariaut; Anuradha Guggilam; Nithya Mariappan; Carrie M Elks; Joseph Francis
Journal:  Hypertension       Date:  2010-08-02       Impact factor: 10.190

4.  Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats.

Authors:  Young Kuk Cho; Gwang Hyeon Eom; Hae Jin Kee; Hyung-Seok Kim; Woo-Yeon Choi; Kwang-Il Nam; Jae Sook Ma; Hyun Kook
Journal:  Circ J       Date:  2010-03-06       Impact factor: 2.993

5.  Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.

Authors:  Douglas D Lemon; Todd R Horn; Maria A Cavasin; Mark Y Jeong; Kurt W Haubold; Carlin S Long; David C Irwin; Sylvia A McCune; Eunhee Chung; Leslie A Leinwand; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2011-04-23       Impact factor: 5.000

6.  HDAC4 deacetylase associates with and represses the MEF2 transcription factor.

Authors:  E A Miska; C Karlsson; E Langley; S J Nielsen; J Pines; T Kouzarides
Journal:  EMBO J       Date:  1999-09-15       Impact factor: 11.598

Review 7.  Histone deacetylases: anti-angiogenic targets in cancer therapy.

Authors:  Denis Mottet; Vincent Castronovo
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

8.  Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.

Authors:  Mercedes Lobera; Kevin P Madauss; Denise T Pohlhaus; Quentin G Wright; Mark Trocha; Darby R Schmidt; Erkan Baloglu; Ryan P Trump; Martha S Head; Glenn A Hofmann; Monique Murray-Thompson; Benjamin Schwartz; Subhas Chakravorty; Zining Wu; Palwinder K Mander; Laurens Kruidenier; Robert A Reid; William Burkhart; Brandon J Turunen; James X Rong; Craig Wagner; Mary B Moyer; Carrow Wells; Xuan Hong; John T Moore; Jon D Williams; Dulce Soler; Shomir Ghosh; Michael A Nolan
Journal:  Nat Chem Biol       Date:  2013-03-24       Impact factor: 15.040

9.  HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy.

Authors:  Joo-Yong Lee; Hiroshi Koga; Yoshiharu Kawaguchi; Waixing Tang; Esther Wong; Ya-Sheng Gao; Udai B Pandey; Susmita Kaushik; Emily Tresse; Jianrong Lu; J Paul Taylor; Ana Maria Cuervo; Tso-Pang Yao
Journal:  EMBO J       Date:  2010-01-14       Impact factor: 11.598

10.  The right ventricle: biologic insights and response to disease.

Authors:  Lori A Walker; Peter M Buttrick
Journal:  Curr Cardiol Rev       Date:  2009-01
View more
  16 in total

Review 1.  The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials (2015 Grover Conference Series).

Authors:  Jessica H Huston; John J Ryan
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

2.  Suberoylanilide hydroxamic acid attenuates paraquat-induced pulmonary fibrosis by preventing Smad7 from deacetylation in rats.

Authors:  Shan-Shan Rao; Xiang-Yan Zhang; Ming-Jun Shi; Ying Xiao; Ying-Ying Zhang; Yuan-Yuan Wang; Chang-Zhi Zhang; Song-Jun Shao; Xin-Mei Liu; Bing Guo
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 3.  Future Perspectives of Pulmonary Hypertension Treatment.

Authors:  Chih-Hsin Hsu; Wei-Chun Huang; Wei-Ting Chang
Journal:  Acta Cardiol Sin       Date:  2022-07       Impact factor: 1.800

Review 4.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

Review 5.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

Review 6.  The Expanding Complexity of Estrogen Receptor Signaling in the Cardiovascular System.

Authors:  Sara Menazza; Elizabeth Murphy
Journal:  Circ Res       Date:  2016-01-07       Impact factor: 17.367

7.  Mechanisms Contributing to the Dysregulation of miRNA-124 in Pulmonary Hypertension.

Authors:  Hui Zhang; Aya Laux; Kurt R Stenmark; Cheng-Jun Hu
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 8.  The Impact of Sex Chromosomes in the Sexual Dimorphism of Pulmonary Arterial Hypertension.

Authors:  Dan N Predescu; Babak Mokhlesi; Sanda A Predescu
Journal:  Am J Pathol       Date:  2022-02-01       Impact factor: 4.307

9.  HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction.

Authors:  Markus Wallner; Deborah M Eaton; Remus M Berretta; Laura Liesinger; Matthias Schittmayer; Juergen Gindlhuber; Jichuan Wu; Mark Y Jeong; Ying H Lin; Giulia Borghetti; Sandy T Baker; Huaqing Zhao; Jessica Pfleger; Sandra Blass; Peter P Rainer; Dirk von Lewinski; Heiko Bugger; Sadia Mohsin; Wolfgang F Graier; Andreas Zirlik; Timothy A McKinsey; Ruth Birner-Gruenberger; Marla R Wolfson; Steven R Houser
Journal:  Sci Transl Med       Date:  2020-01-08       Impact factor: 19.319

Review 10.  Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming.

Authors:  Angelo D'Alessandro; Karim C El Kasmi; Lydie Plecitá-Hlavatá; Petr Ježek; Min Li; Hui Zhang; Sachin A Gupte; Kurt R Stenmark
Journal:  Antioxid Redox Signal       Date:  2017-08-14       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.